Skip to content
TrialScanner

NCT02915523

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Phase 1/Phase 2CompletedSNDXLeadPFECollaborator

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Epithelial Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer
Primary completion
Feb 21, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02915523 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02915523: Study of Avelumab With or... | TrialScanner